Evidence map›Paper›PMID 36423634›Full record

ArticleCell reports. Medicine2022

Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design.

Blake M Hauser, Jared Feldman, Maya Sangesland, Larance Ronsard, Kerri J St Denis, Maegan L Sheehan, Yi Cao, Julie Boucau, Ian W Windsor, Agnes H Cheng and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Blake M HauserRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Jared FeldmanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Maya SangeslandRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Larance RonsardRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Kerri J St DenisRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Maegan L SheehanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Yi CaoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Julie BoucauRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ian W WindsorRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Laboratory of Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Agnes H ChengRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Mya L VuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Marcella R CardosoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Ty KannegieterRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Daniel LingwoodRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Wilfredo F Garcia-BeltranRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Aaron G SchmidtRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: aschmidt@crystal.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USHarvard University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
CDRH3-independent B cell stimulation to selectively expand VRC01 lineages from a fully humanized immunoglobulin repertoireR01AI124378 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2017 to 2020
$2.0M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
NIAID NIH HHS F30 AI160908NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI124378NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI146779NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS T32 AI007245NIAID NIH HHS U19 AI057229NIDA NIH HHS DP2 DA040254NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM008313NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

The emergence of the antigenically distinct and highly transmissible Omicron variant highlights the possibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape due to viral evolution. This continued evolution, along with the possible introduction of new sarbecoviruses from zoonotic reservoirs, may evade host immunity elicited by current SARS-CoV-2 vaccines. Identifying cross-reactive antibodies and defining their epitope(s) can provide templates for rational immunogen design strategies for next-generation vaccines. Here, we characterize the receptor-binding-domain-directed, cross-reactive humoral repertoire across 10 human vaccinated donors. We identify cross-reactive antibodies from diverse gene rearrangements targeting two conserved receptor-binding domain epitopes. An engineered immunogen enriches antibody responses to one of these conserved epitopes in mice with pre-existing SARS-CoV-2 immunity; elicited responses neutralize SARS-CoV-2, variants, and related sarbecoviruses. These data show how immune focusing to a conserved epitope targeted by human cross-reactive antibodies may guide pan-sarbecovirus vaccine development, providing a template for identifying such epitopes and translating to immunogen design.

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodiesCOVID-19 VaccinesEpitopesHumansMiceAntibodiesCOVID-19 VaccinesEpitopesantibodycoronaviruscross-reactiveSARS-CoV-2

Identifiers

PMID36423634
PMCPMC9663748
OpenAlexW4309333180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.